Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation

Rheumatoid arthritis (RA) is preceded by an at-risk stage of disease that can be marked by the presence of anticitrullinated protein antibodies (ACPAs) but the absence of clinically apparent synovitis (clinical RA). Preemptive intervention in at-risk individuals could prevent or delay future tissue damage; however, the immunobiology of this stage is unclear. Using integrative multiomics, we longitudinally profiled at-risk individuals, where one-third of participants developed clinical RA on study. We found evidence of systemic inflammation and signatures of activation in naïve T and B cells of at-risk individuals. During progression to clinical RA, proinflammatory skewing of atypical B cells and expansion of memory CD4 T cells with signatures of activation and B cell help were present without elevations in circulating ACPA titers. Epigenetic changes in naïve CD4 T cells suggested a predisposition to differentiate into effector cells capable of B cell help. These findings characterize pathogenesis of the ACPA<sup>+</sup> at-risk stage and support the concept that the disease begins much earlier than clinical RA. Additionally, an extensive immune resource of the at-risk stage and progression to clinical RA with interactive tools was developed to enable further investigation.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2025-09-24
DOI
https://doi.org/10.1126/scitranslmed.adt7214
Citations
8
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
6.38
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation

Laura Moss, Tylor Thai, Amy Westermann, Vaishnavi Parthasarathy et al.
8 citations
Science Translational Medicine
T-cell and B-cell Immunology
6.38
article

Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation

Laura Moss, Tylor Thai, Amy Westermann, Vaishnavi Parthasarathy, Kevin D. Deane, Veronica Hernandez, Thomas F. Bumol, David L. Boyle, Jane H. Buckner, Vlad Tsaltskan, Gary S. Firestein, Cara Lord, Qiuyu Gong, Chelsie Fleischer, Claire E. Gustafson, Padmapriyadarshini Ravisankar, Lauren Okada, V. Michael Holers, Christopher E. Collora, Palak C. Genge, Nhung T. T. Tran, Leander Lazaro, Adam K. Savage, Mark-Phillip Pebworth, CE Bennett, M. Kristen Demoruelle, Marla C. Glass, Pravina Venkatesan, Ziyuan He, Katherine Nguyen, Christopher C. Striebich, Emma L. Kuan, Charles R. Roll, Elliott Swanson, Ananda W. Goldrath, Lynne A. Becker, Alexander T. Heubeck, Kristine A. Kuhn, Morgan Weiss, Ruoxin Li, Fan Zhang, Upaasana Krishnan, Saman Barzideh, Troy R. Torgerson, Elizabeth A. Bemis, Peter J. Skene, Julian Reading, Lucas T. Graybuck, Zachary Thomson, Samir Rachid Zaim, Mark A. Gillespie, Elisabeth M. Dornisch, Chong Pedrick, Cate Speake, Cole Phalen, Marie L. Feser, Jessica Garber, Hideto Takada, Nguyen Trieu, Jennifer Seifert, Tyanna Stuckey, Brian C. Hattel, Xiaojun Li, Wei Wang, Yudong D. He, Tao Peng, Andrea Ochoa, Christian M. LaFrance, Erin K. Kawelo, Kevin J. Lee, A. Ferrannini, Blessing Musgrove, R Mettey, Najeeb A. Arishi, Ashley G. Asamoah, Megan A. L. Criley, Marguerite D. Siedschlag
article en
8 citations

Abstract

Rheumatoid arthritis (RA) is preceded by an at-risk stage of disease that can be marked by the presence of anticitrullinated protein antibodies (ACPAs) but the absence of clinically apparent synovitis (clinical RA). Preemptive intervention in at-risk individuals could prevent or delay future tissue damage; however, the immunobiology of this stage is unclear. Using integrative multiomics, we longitudinally profiled at-risk individuals, where one-third of participants developed clinical RA on study. We found evidence of systemic inflammation and signatures of activation in naïve T and B cells of at-risk individuals. During progression to clinical RA, proinflammatory skewing of atypical B cells and expansion of memory CD4 T cells with signatures of activation and B cell help were present without elevations in circulating ACPA titers. Epigenetic changes in naïve CD4 T cells suggested a predisposition to differentiate into effector cells capable of B cell help. These findings characterize pathogenesis of the ACPA<sup>+</sup> at-risk stage and support the concept that the disease begins much earlier than clinical RA. Additionally, an extensive immune resource of the at-risk stage and progression to clinical RA with interactive tools was developed to enable further investigation.

Science Translational MedicineVol. 17(817)
University of California San Diego (US), Society of Interventional Radiology (US), Allen Institute for Immunology (US), University of Colorado Anschutz Medical Campus (US)
Openalex Percentile: Top 3%
T-cell and B-cell Immunology
6.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.